Live Bevacizumab updates

Live Bevacizumab news coverage of developments with the latest updates. Stay on top of latest Bevacizumab news stories and find out what just happened, what is going on with Bevacizumab. The latest real-time news updates and headlines on Bevacizumab
EMA Validates Henlius, Organon's HLX14 Biosimilar Filings
ASCO: Combo Therapy Boosts Metastatic Colorectal Cancer Outcomes
FDA Fully Approves TIVDAK for Recurrent, Metastatic Cervical Cancer
FivepHusion Gets Ethics Nod for Phase 1b Trial of Deflexifol
Drug Combo Boosts Antibacterial Delivery in Rabbits
Combined Drugs Boost Anti-Bacterial Tuberculosis Treatment
Machine Learning Model Predicts Oxaliplatin Benefit: Study
UPV-Led Study Paves Way for Enhanced Glioblastoma Treatment
Imfinzi Combo Reduces Liver Cancer Progression Risk by 23%
FDA Prioritizes Review of TIVDAK for Metastatic Cervical Cancer
Chemo and Anti-Tumor Drugs Combo May Boost Kids' Cancer Outcomes
Imfinzi and Bevacizumab Hit Endpoint in Liver Cancer Trial
Special Edition: ESMO 2023 Key Findings from MD Anderson
Aggressive Treatment No Threat to Life Quality in Colorectal Cancer: Study
Personalized Vaccine and T Cell Therapy Aid Advanced Ovarian Cancer
Precision Approach Slashes Oncology Drug Development Costs by $1B
Allarity, FivepHusion Partner to Develop Deflexifol, DRP Diagnostics
TGA Product Information safety updates 23 June
New Combination Drug Reduces Risk of Disease Progression in Ovarian Cancer
AstraZeneca to Showcase Practice-Changing Cancer Drugs at ASCO 2023
Mays Cancer Center Conducts Only US Clinical Trial of Drug Combo for Glioblastoma
Over Half of English NSCLC Patients in Low Socio-Economic Areas Not Receiving New Anti-Cancer Therapies
Dana-Farber Faculty to Showcase 50+ Studies at AACR Meeting 2023
Adding Bevacizumab to Targeted Drug and Chemotherapy Shows Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Lynparza and Imfinzi combo boosts survival in advanced ovarian cancer patients
Promising Molecular Targets Identified for Cervical Cancer Drugs
Normalizing Blood Vessels May Boost Immunotherapy for Brain Cancer
1/3 of Drug-Resistant Ovarian Cancer Patients Find Remission with Conjugate Therapy
Advanced Cervical Cancer: Pembrolizumab Prolongs Life Span
Plasma GH Predicts Response to Atezolizumab & Bevacizumab in HCC
Product Information safety updates
One of Two Widely Used Macular Degeneration Drugs Outperforms Other at Weaning Patients Off Treatment at One Year
Localising BRCA gene mutations to better treat ovarian cancer
Dana-Farber research supports FDA approval of new therapy for certain patients with ovarian cancer
Study Points Toward New Ways to Prevent Liver Cancer
Lynparza approved in China as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
Ludwig Lausanne study identifies potential combination therapy for testing in deadly brain cancer
Lynparza in combination with bevacizumab, and as monotherapy, demonstrates clinically meaningful survival benefit
Lynparza approved in Japan as adjuvant treatment for patients with BRCA-mutated HER2-negative high-risk early breast cancer
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
Lynparza approved in EU as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer
Type of 'step therapy' is effective strategy for diabetic eye disease
Johns Hopkins Researchers Call for Closing Gap in Collecting Racial and Ethnic Data
Lynparza recommended for approval in EU by CHMP as adjuvant treatment for patients with germline BRCA-mutated HER2-negative
UCSF Cancer Specialists to Present Clinical Findings at Major Conference
How have hepatocellular carcinoma treatments improved?
Vision improvement is long-lasting with treatment for blinding blood vessel condition
MD Anderson research highlights for April 13, 2022